European Journal of Clinical Pharmacology

Papers
(The H4-Index of European Journal of Clinical Pharmacology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
How to make the best of NLRP3 inhibitors in patients with COVID-19?99
A Study Of the effect of Sex on drug dosing, concentrations, and pharmacogenomics in the Montreal Heart Institute Hospital Cohort (SOS-PGx): methodology and research progress35
Might chronic spontaneous urticaria develop after SARS-CoV-2 vaccinations?35
Medication adherence among persons with coronary heart disease and associations with blood pressure and low-density-lipoprotein-cholesterol34
Association study identifies genetic determinants and non-genetic factors on steady-state plasma and therapeutic outcome of galantamine in mixed dementia33
Use of overactive bladder anticholinergic medications associated with falls leading to emergency department visits: results from the ADRED study32
Usefulness of mirtazapine and SSRIs in late-life depression: post hoc analysis of the GUNDAM study26
A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease25
Signal detection between 5-alpha reductase inhibitors and the risk of suicidality and depression: an international pharmacovigilance analysis25
Incidence and risk factors of drug-induced kidney injury in children: a systematic review and meta-analysis24
Anticholinergic burden and cognitive performance: cross-sectional results from the ELSA-Brasil study24
The efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with left-sided bioprosthetic heart valves and atrial fibrillation: a systematic review and meta-analysis22
Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans22
Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteers22
Self-reported adherence to direct oral anticoagulants versus warfarin therapy in a specialized thrombosis service—a cross-sectional study of patients in a Canadian Health Region21
Comment on “Use of statins and risks of ovarian, uterine, and cervical diseases: a cohort study in the UK Biobank”21
Clinical pharmacology—how it shapes the drug development journey19
Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data19
Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials18
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation18
Relationship between CYP2C8, UGT1A1, and ABCG2 gene polymorphisms and the exposure, efficacy, and toxicity of eltrombopag in the treatment of refractory aplastic anemia18
Dose reduction and discontinuation due to the combination of CDK4/6 inhibitors and endocrine drugs: a systematic review and meta-analysis18
Prevalence, contributory factors and severity of medication errors associated with direct-acting oral anticoagulants in adult patients: a systematic review and meta-analysis18
Challenges of pediatric pharmacotherapy: A narrative review of pharmacokinetics, pharmacodynamics, and pharmacogenetics18
Effect of GLP-1R rs2254336 and rs3765467 polymorphisms on gastrointestinal adverse reactions in type 2 diabetes patients treated with liraglutide18
Pharmacokinetics of mycophenolic acid and external evaluation of two limited sampling strategies of drug exposure in patients with juvenile systematic lupus erythematosus18
Pharmacoepidemiological methods for computing the duration of pharmacological prescriptions using secondary data sources18
0.089612007141113